Enliven Therapeutics GAAP EPS of -$0.48 beats by $0.02

Enliven Therapeutics press release ( NASDAQ: ELVN ): Q3 GAAP EPS of -$0.48 beats by $0.02 .

As of September 30, 2024, the Company had cash, cash equivalents and marketable securities totaling $291.8 million. Net loss was $23.



2 million for the third quarter of 2024, compared to $20.8 million for the third quarter of 2023. More on Enliven Therapeutics Seeking Alpha’s Quant Rating on Enliven Therapeutics Historical earnings data for Enliven Therapeutics Financial information for Enliven Therapeutics.